v3.26.3
Supplemental Income Statement Information
 9 Months Ended
Sep. 26, 2026
Supplemental Income Statement Elements [Abstract]  
Supplemental Income Statement Information Supplemental Income Statement Information
Disaggregated Revenues
Revenues by type are as follows:
Three months endedNine months ended
(In millions)September 26, 2026September 27, 2025September 26, 2026September 27, 2025
Revenues
Consumables
$4,870 $4,679 $14,665 $13,638 
Instruments
1,883 1,811 5,188 5,080 
Services
5,384 4,633 15,283 13,623 
Consolidated revenues$12,137 $11,122 $35,136 $32,341 
Revenues by geographic region based on customer location are as follows:
Three months endedNine months ended
(In millions)September 26, 2026September 27, 2025September 26, 2026September 27, 2025
Revenues
North America
$6,266 $5,689 $18,120 $16,924 
Europe
3,201 3,005 9,469 8,459 
Asia-Pacific
2,240 2,013 6,314 5,824 
Other regions
430 415 1,232 1,135 
Consolidated revenues$12,137 $11,122 $35,136 $32,341 
Each reportable segment earns revenues from consumables, instruments and services in North America, Europe, Asia-Pacific and other regions.
Revenues by business are as follows:
Three months endedNine months ended
(In millions)
September 26, 2026September 27, 2025September 26, 2026September 27, 2025
Revenues



Biosciences
$1,025 $1,023 $3,065 $3,091 
Genetic sciences
702 720 2,060 2,076 
BioProduction
896 817 2,730 2,234 
Other
96 28 315 27 
Life Sciences Solutions
2,719 2,588 8,170 7,428 
Chromatography and mass spectrometry
859 841 2,478 2,398 
Chemical analysis
316 320 919 898 
Electron microscopy
827 732 2,167 2,043 
Analytical Instruments
2,002 1,893 5,564 5,339 
Clinical diagnostics
269 283 830 822 
ImmunoDiagnostics
232 230 710 681 
Microbiology
70 162 396 473 
Transplant diagnostics
131 125 386 362 
Healthcare market channel
454 444 1,326 1,325 
Elimination of intrasegment revenues
(58)(70)(204)(207)
Specialty Diagnostics
1,098 1,174 3,445 3,456 
Laboratory products
603 594 1,779 1,776 
Research and safety market channel
2,030 1,861 5,893 5,471 
Pharma services
2,029 1,722 5,662 5,123 
Clinical research
2,445 2,019 6,969 5,914 
Elimination of intrasegment revenues and other
(242)(226)(710)(679)
Laboratory Products and Biopharma Services
6,863 5,970 19,592 17,605 
Elimination of intersegment revenues
(546)(503)(1,635)(1,487)
Consolidated revenues$12,137 $11,122 $35,136 $32,341 
Restructuring and Other Costs
In the first nine months of 2026, restructuring and other costs primarily included impairments of long-lived assets, continuing charges for headcount reductions and facility consolidations in an effort to streamline operations, and, to a lesser extent, net charges for pre-acquisition litigation and other matters, partially offset by gain on the sale of a business. In 2026, severance actions associated with facility consolidations and cost reduction measures affected approximately 2% of the company’s workforce.
As of October 30, 2026, the company has identified restructuring actions, primarily in the Laboratory Products and Biopharma Services segment, that it expects will result in additional charges of approximately $180 million, primarily in 2026, and expects to identify additional actions in future periods.
Restructuring and other costs are as follows:
Three months endedNine months ended
(In millions)September 26, 2026September 26, 2026
Life Sciences Solutions
$2 $25 
Analytical Instruments
1 22 
Specialty Diagnostics
(60)(57)
Laboratory Products and Biopharma Services
256 350 
Corporate
1 7 
$199 $346 
The following table summarizes the changes in the company’s accrued restructuring balance, which is included in other accrued expenses in the accompanying balance sheets. Other amounts reported as restructuring and other costs in the accompanying statements of income are summarized in the notes to the table.
(In millions)Total (a)
Balance at December 31, 2025$70 
Net restructuring charges incurred in 2026 (b)
101 
Payments(90)
Currency translation and other(4)
Balance at September 26, 2026$75 
(a)The movements in the restructuring liability principally consist of severance and other costs associated with facility consolidations.
(b)Excludes $246 million of net charges, including $244 million for a held-for-sale loss in the Laboratory Products and Biopharma Services segment and $72 million of gain on sale of the microbiology business in the Specialty Diagnostics segment.
The company expects to pay accrued restructuring costs primarily through 2026.
Earnings per Share
The company’s earnings per share are as follows:
Three months endedNine months ended
September 26,September 27,September 26,September 27,
(In millions except per share amounts)2026202520262025
Net income attributable to Thermo Fisher Scientific Inc.$1,721 $1,616 $5,108 $4,740 
Basic weighted average shares370 378 371 378 
Plus effect of: stock options and restricted stock units1 1 1 1 
Diluted weighted average shares371 378 372 378 
Basic earnings per share$4.65 $4.28 $13.77 $12.55 
Diluted earnings per share$4.64 $4.27 $13.75 $12.53 
Antidilutive stock options excluded from diluted weighted average shares
2 3 3 3